Virtus ETF Advisers LLC Raises Stock Holdings in Immatics (NASDAQ:IMTX)

Virtus ETF Advisers LLC increased its position in Immatics (NASDAQ:IMTX) by 34.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 9,594 shares of the company’s stock after purchasing an additional 2,479 shares during the period. Virtus ETF Advisers LLC’s holdings in Immatics were worth $68,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Immatics by 24.6% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company’s stock worth $163,000 after purchasing an additional 4,477 shares during the period. Guggenheim Capital LLC purchased a new stake in Immatics in the fourth quarter worth $101,000. State Street Corp grew its stake in Immatics by 11.2% in the third quarter. State Street Corp now owns 225,202 shares of the company’s stock worth $2,570,000 after purchasing an additional 22,710 shares during the period. Aristides Capital LLC purchased a new stake in Immatics in the fourth quarter worth $205,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Immatics in the fourth quarter worth $211,000. 64.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Immatics in a research note on Tuesday, April 1st. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Immatics currently has an average rating of “Buy” and an average target price of $16.67.

Immatics Trading Up 5.5 %

NASDAQ IMTX opened at $4.77 on Tuesday. Immatics has a 12 month low of $3.30 and a 12 month high of $13.77. The stock has a market cap of $579.79 million, a P/E ratio of -7.23 and a beta of 0.85. The stock’s fifty day moving average price is $4.42 and its 200-day moving average price is $6.28.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings results on Thursday, March 27th. The company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.51. The firm had revenue of $15.67 million for the quarter, compared to the consensus estimate of $16.16 million. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. As a group, analysts forecast that Immatics will post -0.72 earnings per share for the current fiscal year.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.